SAN CLEMENTE, Calif.,
April 18, 2018 /PRNewswire/ --
ReShape Lifesciences Inc. (NASDAQ:RSLS), a developer of minimally
invasive medical devices to treat obesity and metabolic diseases,
announced today that over 40 surgeons were trained to implant the
ReShape BalloonTM during the Society of American
Gastrointestinal and Endoscopic Surgeons (SAGES) 2018 /16th World
Congress that was held in Seattle
from April 11-14, 2018.
ReShape Lifesciences was a participant in the Endoscopic Surgery
Bariatric Endoscopy Hands-On Course that was held as part of
SAGES. One of the course objectives was for the participating
endoscopic surgeons to learn to integrate emerging technologies for
weight-loss into their practices through hands-on experience.
Over 40 surgeons chose to be educated and trained on the ReShape
Balloon technology during the course.
SAGES has over 6,000 members around the world. For more
details on SAGES, please visit http://www.sages.org.
About ReShape Lifesciences Inc.
ReShape Lifesciences™ is a medical device company focused on
technologies to treat obesity and metabolic diseases. The
FDA-approved ReShape Balloon™ System involves a non-surgical weight
loss procedure that uses advanced balloon technology designed to
take up room in the stomach to help people with a 30-40
kg/m2 Body Mass Index (BMI) and at least one
co-morbidity lose weight. ReShape vBloc™ Therapy, delivered by an
FDA-approved pacemaker-like device called the ReShape vBloc System,
is designed to help patients with a 40-45 kg/m2, or a
35-39.9 kg/m2 BMI and at least one co-morbidity feel
full and eat less by intermittently blocking hunger signals on the
vagus nerve. The ReShape Vest™ System is an investigational,
minimally invasive, laparoscopically implanted medical device that
wraps around the stomach, emulating the gastric volume reduction
effect of conventional weight-loss surgery, and is intended to
enable rapid weight loss in obese and morbidly obese patients
without permanently changing patient anatomy.
Forward-Looking Safe Harbor Statement:
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These forward-looking statements generally can be identified
by the use of words such as "expect," "plan," "anticipate,"
"could," "may," "intend," "will," "continue," "future," other words
of similar meaning and the use of future dates. These
forward-looking statements are based on the current expectations of
our management and involve known and unknown risks and
uncertainties that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements. Such risks and uncertainties include,
among others: risks and uncertainties related to our acquisitions
of ReShape Medical, Inc. and BarioSurg, Inc.; risks related to the
U.S. Food and Drug Administration's announcement to alert health
care providers of unanticipated deaths involving the ReShape
Balloon; our proposed ReShape Vest product may not be successfully
developed and commercialized; our ability to continue as a going
concern if we are unsuccessful in our pursuit of various funding
options; our limited history of operations; our losses since
inception and for the foreseeable future; our limited commercial
sales experience; the competitive industry in which we operate; our
ability to maintain compliance with the Nasdaq continued listing
requirements; our dependence on third parties to initiate and
perform our clinical trials; the need to obtain regulatory approval
for our ReShape Vest and any modifications to our vBloc system or
ReShape Balloon; physician adoption of our products; our ability to
obtain third party coding, coverage or payment levels; ongoing
regulatory compliance; our dependence on third party manufacturers
and suppliers; the successful development of our sales and
marketing capabilities; our ability to raise additional capital
when needed; international commercialization and operation; our
ability to attract and retain management and other personnel and to
manage our growth effectively; potential product liability claims;
the cost and management time of operating a public company;
potential healthcare fraud and abuse claims; healthcare legislative
reform; and our ability to obtain and maintain intellectual
property protection for our technology and products. These and
additional risks and uncertainties are described more fully in the
Company's filings with the Securities and Exchange Commission,
particularly those factors identified as "risk factors" in our
annual report on Form 10-K filed April 2, 2018. We are
providing this information as of the date of this press release and
do not undertake any obligation to update any forward-looking
statements contained in this document as a result of new
information, future events or otherwise.
View original content with
multimedia:http://www.prnewswire.com/news-releases/forty-surgeons-trained-on-reshape-balloon-at-hands-on-course-during-sages-2018-300631945.html
SOURCE ReShape Lifesciences Inc.